| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $42.3M | — |
| R&D Expense | $44.6M | +158.9% |
| SG&A Expense | $149.8M | +197.4% |
| Operating Income | -$154.6M | -128.8% |
| Pre-tax Income | -$163.1M | -202.7% |
| Income Tax | $10.3M | +2070.7% |
| Net Income | -$173.4M | -219.0% |
| EPS (Basic) | -$0.27 | -200.0% |
| EPS (Diluted) | -$0.27 | -200.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $399.8M | +47.1% |
| Accounts Receivable | $31.5M | — |
| Inventory | $6.2M | — |
| Current Assets | $453.6M | +56.6% |
| Total Assets | $474.2M | +53.9% |
| Current Liabilities | $42.7M | +391.0% |
| Long-term Debt | $120.3M | +140.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$122.2M | -143.3% |
| Capital Expenditures | $580K | — |
| Investing Cash Flow | -$580K | — |
| Financing Cash Flow | $250.8M | +170.0% |
| Free Cash Flow | -$122.8M | -144.5% |
| Total Liabilities |
| $269.7M |
| +358.3% |
| Stockholders' Equity | $204.6M | -17.9% |